Recent Publications By Kuick Research Highlights Emergence Of Antibodies As Fundamental Premise For The Growth Of Targeted Cancer Drug Market Market.
Recent Publications By Kuick Research Highlights Emergence Of Antibodies As Fundamental Premise For The Growth Of Targeted Cancer Drug Market Market
Technological advancements such as gene sequencing and target gene selection have led to introduction of targeted therapies in the management of cancer. Amid all therapies, antibody therapeutics have emerged as shining star in the global market owing to their ability to specifically target the disease and generating specific immune response against it. Till date, a number of antibody therapeutics has gained approval in the global market which belong to various different classes including monoclonal antibodies, bispecific antibodies, and antibody drug conjugates.
- Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028
- Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028
- Global Lung Cancer Antibodies Market, Drug Sales & Clinical Trials Insight 2028
- Global Lymphoma Antibodies Market & Clinical Trials Insight 2028
- Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028
- Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2028
- US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028
Download Reports:
https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
Monoclonal antibodies are currently dominating the global market owing to large number of drugs approved. Despite its huge success, there was need of more enhanced therapeutics which can target the multifactorial nature of the cancer. This has led to introduction of bispecific antibodies which are designed to possess the epitope specificity and manufacturability of a conventional monoclonal antibody but are engineered to bind two distinct targets instead of one. Development and commercialization of bispecific antibodies, to engage multiple targets using only one therapeutic, has gained significant attention recently, shifting industry focus and investments on this effective therapeutic strategy. Currently, three bispecific antibodies have gained approval including Blincyto, Rybrevant, and Lunsumio.
Antibody drug conjugates are next generation drug class which consists of 3 parts: an antibody drug that is specific for the type of cancer being targeted, a cytotoxic chemotherapy drug, and a linker protein to hold the 2 parts together. Till date, 15 antibody drug conjugates have been granted approval which has shown promising response in the management of wide range of cancers. Apart from approved antibody drug conjugates, more than 100 are present in clinical development which is expected to enter the market during the forecast period, thus indicating future potential of this therapeutics in the management of cancer. For instance, MediLink Therapeutics announced that YL201, the first compound based on MediLink’s proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the US FDA.
Further, enhancement in the field of biotechnology and unmet need of more efficient drugs has also led to development of trispecific antibodies which are currently present in clinical development. HPN328 developed by Harpoon Therapeutics is an investigational DLL3 targeting TriTAC which is being evaluated in phase-I/II clinical for the management of patients with small cell lung cancer, neuroendocrine and other DLL3-associated tumors. The preliminary results from the trial suggest that HPN328 was well tolerated and was not associated with any treatment related adverse events. Other trispecific antibodies in development include GTB3550, GTB4550, HPN217, NM21 -1480, SAR443216, and others.
Apart from monotherapy, ongoing clinical trials are also evaluating the role of combination therapy to enhance the efficacy of antibody therapeutics and overcome drug resistance. The key players in the market have entered into partnerships, collaboration, or joint ventures to analyze different combinations to enhance the efficacy of antibody therapeutics. For instance in 2021, Enlivex and Mount Sinai Health announced research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors. The agreement aims to develop preclinical program to investigate the potential synergies between Allocetra and commercially approved checkpoint inhibitor therapies for select solid cancers. Allocetra developed by Enlivex is macrophage reprogramming immunotherapeutic drug indicated for life-threatening immune mediated disease.
As per our report findings, the global cancer antibodies market is expected to surpass US$ 130 Billion by 2028. The major factor boosting the growth of market includes the rising prevalence of cancer and unmet need of targeted therapy in its management. In addition, the encouraging response of antibody therapy over other approved therapies is another factor propelling the growth of market. Moreover, huge pharmaceutical investments and clinical trials are also boosting the market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com